It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Circadian clocks coordinate mammalian behavior and physiology enabling organisms to anticipate 24-hour cycles. Transcription-translation feedback loops are thought to drive these clocks in most of mammalian cells. However, red blood cells (RBCs), which do not contain a nucleus, and cannot perform transcription or translation, nonetheless exhibit circadian redox rhythms. Here we show human RBCs display circadian regulation of glucose metabolism, which is required to sustain daily redox oscillations. We found daily rhythms of metabolite levels and flux through glycolysis and the pentose phosphate pathway (PPP). We show that inhibition of critical enzymes in either pathway abolished 24-hour rhythms in metabolic flux and redox oscillations, and determined that metabolic oscillations are necessary for redox rhythmicity. Furthermore, metabolic flux rhythms also occur in nucleated cells, and persist when the core transcriptional circadian clockwork is absent in Bmal1 knockouts. Thus, we propose that rhythmic glucose metabolism is an integral process in circadian rhythms.
Red blood cells, which do not possess a nucleus, have circadian redox rhythms with incompletely understood regulatory mechanisms. Here the authors show that glucose metabolism plays a crucial role in regulating circadian redox status of human red blood cells.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 University of Cambridge Metabolic Research Laboratories, Institute of Metabolic Science, University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK (GRID:grid.470900.a) (ISNI:0000 0004 0369 9638); Queen’s University Belfast, School of Biological Sciences, Belfast, UK (GRID:grid.4777.3) (ISNI:0000 0004 0374 7521)
2 University of Cambridge Metabolic Research Laboratories, Institute of Metabolic Science, University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK (GRID:grid.470900.a) (ISNI:0000 0004 0369 9638); Unilabs Genetics Laboratory, Lausanne, Switzerland (GRID:grid.470900.a)
3 University of Pennsylvania, Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, Pennsylvania, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972); University of Pennsylvania, Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972); Indian Institute of Technology Hyderabad, Department of Biotechnology, Kandi, Sangareddy, India (GRID:grid.459612.d) (ISNI:0000 0004 1767 065X)
4 University of Pennsylvania, Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, Pennsylvania, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972); University of Pennsylvania, Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972)
5 The Francis Crick Institute, London, UK (GRID:grid.451388.3) (ISNI:0000 0004 1795 1830)
6 University of Cambridge Metabolic Research Laboratories, Institute of Metabolic Science, University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK (GRID:grid.470900.a) (ISNI:0000 0004 0369 9638); University of Cambridge, Department of Oncology, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934)
7 University of Pennsylvania, Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, Pennsylvania, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972); University of Pennsylvania, Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972); University of Pennsylvania Perelman School of Medicine, Institute for Diabetes, Obesity, and Metabolism, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972); University of Pennsylvania, Chronobiology and Sleep institute (CSI), Perelman School of Medicine, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972)